Organon & Co. (NYSE:OGN) Announces Quarterly Dividend of $0.28

Organon & Co. (NYSE:OGN) announced a quarterly dividend on Tuesday, August 6th, Zacks reports. Shareholders of record on Friday, August 16th will be given a dividend of 0.28 per share on Thursday, September 12th. This represents a $1.12 dividend on an annualized basis and a yield of 5.75%. The ex-dividend date of this dividend is Friday, August 16th.

Organon & Co. has a dividend payout ratio of 24.3% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Organon & Co. to earn $4.31 per share next year, which means the company should continue to be able to cover its $1.12 annual dividend with an expected future payout ratio of 26.0%.

Organon & Co. Stock Performance

Organon & Co. stock traded up $0.84 during mid-day trading on Wednesday, reaching $19.49. 490,147 shares of the company were exchanged, compared to its average volume of 2,282,178. Organon & Co. has a twelve month low of $10.84 and a twelve month high of $24.08. The firm’s 50-day simple moving average is $20.82 and its two-hundred day simple moving average is $19.28. The company has a debt-to-equity ratio of 181.35, a quick ratio of 1.15 and a current ratio of 1.65. The firm has a market cap of $5.01 billion, a PE ratio of 4.56, a price-to-earnings-growth ratio of 1.01 and a beta of 0.85.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.12 EPS for the quarter, beating the consensus estimate of $1.08 by $0.04. The business had revenue of $1.61 billion during the quarter, compared to analysts’ expectations of $1.61 billion. Organon & Co. had a negative return on equity of 360.57% and a net margin of 16.50%. The company’s quarterly revenue was down .1% compared to the same quarter last year. During the same period last year, the firm earned $1.31 EPS. Equities analysts predict that Organon & Co. will post 4.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

OGN has been the subject of several recent research reports. The Goldman Sachs Group raised their price target on Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Piper Sandler boosted their price target on Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Monday, April 29th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.